461 related articles for article (PubMed ID: 25761977)
21. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Yang LP
Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
[TBL] [Abstract][Full Text] [Related]
22. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus.
Karyekar CS; Ravichandran S; Allen E; Fleming D; Frederich R
Clin Interv Aging; 2013; 8():419-30. PubMed ID: 23626461
[TBL] [Abstract][Full Text] [Related]
23. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension.
Kadowaki T; Muto S; Ouchi Y; Shimazaki R; Seino Y
Expert Opin Pharmacother; 2017 Dec; 18(18):1903-1919. PubMed ID: 28901796
[TBL] [Abstract][Full Text] [Related]
25. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Göke B; Gallwitz B; Eriksson JG; Hellqvist Å; Gause-Nilsson I
Int J Clin Pract; 2013 Apr; 67(4):307-16. PubMed ID: 23638466
[TBL] [Abstract][Full Text] [Related]
26. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
[TBL] [Abstract][Full Text] [Related]
28. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin.
Matthaei S; Aggarwal N; Garcia-Hernandez P; Iqbal N; Chen H; Johnsson E; Chin A; Hansen L
Diabetes Obes Metab; 2016 Nov; 18(11):1128-1133. PubMed ID: 27403645
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
Gu S; Deng J; Shi L; Mu Y; Dong H
J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Frias JP; Gonzalez-Galvez G; Johnsson E; Maaske J; Testa MA; Simonson DC; Dronamraju N; Garcia-Sanchez R; Peters AL
Diabetes Obes Metab; 2020 Jul; 22(7):1083-1093. PubMed ID: 32052516
[TBL] [Abstract][Full Text] [Related]
31. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials.
Cook W; Minervini G; Bryzinski B; Hirshberg B
Postgrad Med; 2014 Oct; 126(6):19-32. PubMed ID: 25414932
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
Terauchi Y; Yamada Y; Ishida H; Ohsugi M; Kitaoka M; Satoh J; Yabe D; Shihara N; Seino Y
Diabetes Obes Metab; 2017 Aug; 19(8):1188-1192. PubMed ID: 28294488
[TBL] [Abstract][Full Text] [Related]
33. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
34. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
[TBL] [Abstract][Full Text] [Related]
35. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Schweizer A; Dejager S; Bosi E
Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
[TBL] [Abstract][Full Text] [Related]
36. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Handelsman Y; Mathieu C; Del Prato S; Johnsson E; Kurlyandskaya R; Iqbal N; Garcia-Sanchez R; Rosenstock J
Diabetes Obes Metab; 2019 Apr; 21(4):883-892. PubMed ID: 30499237
[TBL] [Abstract][Full Text] [Related]
37. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
[TBL] [Abstract][Full Text] [Related]
38. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.
Nowicki M; Rychlik I; Haller H; Warren ML; Suchower L; Gause-Nilsson I;
Diabetes Obes Metab; 2011 Jun; 13(6):523-32. PubMed ID: 21332627
[TBL] [Abstract][Full Text] [Related]
39. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.
Pfützner A; Paz-Pacheco E; Allen E; Frederich R; Chen R;
Diabetes Obes Metab; 2011 Jun; 13(6):567-76. PubMed ID: 21342412
[TBL] [Abstract][Full Text] [Related]
40. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]